Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
Outline of Final Research Achievements |
We recently generated transgenic mice with enhanced phospholipase C-delta 1 activity (PLC-TG) and reported enhanced coronary vasomotility such as that seen in patients with coronary spastic angina. In the present study, we showed the efficacy of calcium antagonist for coronary spasm and its mechanism using the PLC-TG mice. Alterations in activity of calcium channels were suggested to be implicated in the therapeutic effect of calcium antagonist. Furthermore, we first clarified roles of A-kinase anchoring proteins in the coronary spasm. The present study may help better understand mechanism of the coronary spasm and contribute to the development of novel treatment strategy for drug-resistant coronary spasm.
|